Depakote ER (DIVALPROEX SODIUM)
Depakote ER (DIVALPROEX SODIUM) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Depakote ER; Generic name: DIVALPROEX SODIUM; Manufacturer: AbbVie Inc..
| Brand name | Depakote ER |
|---|---|
| Generic name | DIVALPROEX SODIUM |
| Manufacturer | AbbVie Inc. |
| Used for | 1 INDICATIONS AND USAGE Depakote ER is indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) Prophylaxis of migraine headaches ( 1.3 ) 1.1 Mania Depakote ER is a valproate and is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. |
| Dosage | 2 DOSAGE AND ADMINISTRATION Depakote ER is an extended-release product intended for once-a-day oral administration. Depakote ER tablets should be swallowed whole and should not be crushed or chewed. Depakote ER is intended for once-a-day oral administration. Depakote ER should be swallowed whole and should not be crushed or chewed ( 2.1 , 2.2 ). Mania: Initial dose is 25 mg/kg/day, increasing as rapidly as possible to achieve therapeutic response or desired plasma level ( 2.1 ). The maximum reco |
| Warnings | WARNING: LIFE THREATENING ADVERSE REACTIONS Hepatotoxicity General Population: Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be |
| Active ingredient(s) | DIVALPROEX SODIUM |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dc024ce-efc8-4690-7cb5-639c728fccac |